Cargando…

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial

Gaucher disease type 3 is a chronic neuronopathic disorder with wide-ranging effects, including hepatosplenomegaly, anaemia, thrombocytopenia, skeletal disease and diverse neurological manifestations. Biallelic mutations in GBA1 reduce lysosomal acid β-glucosidase activity, and its substrates, gluco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schiffmann, Raphael, Cox, Timothy M, Dedieu, Jean-François, Gaemers, Sebastiaan J M, Hennermann, Julia B, Ida, Hiroyuki, Mengel, Eugen, Minini, Pascal, Mistry, Pramod, Musholt, Petra B, Scott, David, Sharma, Jyoti, Peterschmitt, M Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924909/ https://www.ncbi.nlm.nih.gov/pubmed/36256599 http://dx.doi.org/10.1093/brain/awac379

Ejemplares similares

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Imiglucerase in the treatment of Gaucher disease: a history and perspective
por: Deegan, Patrick B, et al.
Publicado: (2012)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
por: Peterschmitt, M. Judith, et al.
Publicado: (2022)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
por: Xu, You-Hai, et al.
Publicado: (2010)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)

Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
por: Doneda, Divair, et al.
Publicado: (2013)

Achievement of Therapeutic Goals with Low-Dose Imiglucerase in Gaucher Disease: A Single-Center Experience
por: Tukan, Irina, et al.
Publicado: (2013)

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
por: Serratrice, Christine, et al.
Publicado: (2016)

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1
por: Stirnemann, Jérôme, et al.
Publicado: (2015)

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2012)

Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3
por: Machaczka, Maciej, et al.
Publicado: (2014)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2013)

Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series
por: Serratrice, Christine, et al.
Publicado: (2015)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades
por: Hopf, Susanne, et al.
Publicado: (2019)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
por: Sidhu, Karamjot, et al.
Publicado: (2020)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
por: Sims, KB, et al.
Publicado: (2008)

Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Gba1 Mutant Mouse Model Treated with Velaglucerase alfa or Imiglucerase
por: Dasgupta, Nupur, et al.
Publicado: (2013)

Retinal thinning in phenylketonuria and Gaucher disease type 3
por: Hopf, Susanne, et al.
Publicado: (2021)

Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological Findings
por: Bremova-Ertl, Tatiana, et al.
Publicado: (2018)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

The cognitive profile of type 1 Gaucher disease patients
por: Biegstraaten, Marieke, et al.
Publicado: (2012)

Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers
por: Li, Yingxin, et al.
Publicado: (2023)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_li0nauqdl2k4u2hmsh0vbiv39p